{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:42:20Z","timestamp":1789015340240,"version":"build-2803163510"},"reference-count":20,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Improving survival outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL) remains a clinical challenge. Relapsed disease has a poor prognosis despite the use of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome positive (Ph+ ALL) cases and immunotherapeutic approaches, including blinatumomab and chimeric antigen receptor T cells. Targeting aberrant cell survival pathways with selective small molecule BH3-mimetic inhibitors of BCL-2 (venetoclax, S55746), BCL-XL (A1331852), or MCL1 (S63845) is an emerging therapeutic option. We report that combined targeting of BCL-2 and MCL1 is synergistic in B-ALL in vitro. The combination demonstrated greater efficacy than standard chemotherapeutics and TKIs in primary samples from adult B-ALL with Ph+ ALL, Ph-like ALL, and other B-ALL. Moreover, combined BCL-2 or MCL1 inhibition with dasatinib showed potent killing in primary Ph+ B-ALL cases, but the BH3-mimetic combination appeared superior in vitro in a variety of Ph-like ALL samples. In PDX models, combined BCL-2 and MCL1 targeting eradicated ALL from Ph\u2212 and Ph+ B-ALL cases, although fatal tumor lysis was observed in some instances of high tumor burden. We conclude that a dual BH3-mimetic approach is highly effective in diverse models of high-risk human B-ALL and warrants assessment in clinical trials that incorporate tumor lysis precautions.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001416","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T15:39:45Z","timestamp":1592840385000},"page":"2762-2767","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Cotargeting BCL-2 and MCL-1 in high-risk B-ALL"],"prefix":"10.1182","volume":"4","author":[{"given":"Donia M.","family":"Moujalled","sequence":"first","affiliation":[{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;"},{"name":"Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane T.","family":"Hanna","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"},{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"},{"name":"The Royal Children\u2019s Hospital, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-6779","authenticated-orcid":false,"given":"Soroor","family":"Hediyeh-zadeh","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"},{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Pomilio","sequence":"first","affiliation":[{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;"},{"name":"Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4322-8203","authenticated-orcid":false,"given":"Lauren","family":"Brown","sequence":"first","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Litalien","sequence":"first","affiliation":[{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Bartolo","sequence":"first","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Fleming","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00efa","family":"Chanrion","sequence":"first","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Banquet","sequence":"first","affiliation":[{"name":"Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Leticia","family":"Maragno","sequence":"first","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Kraus-Berthier","sequence":"first","affiliation":[{"name":"Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Schoumacher","sequence":"first","affiliation":[{"name":"Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-1850","authenticated-orcid":false,"given":"Charles G.","family":"Mullighan","sequence":"first","affiliation":[{"name":"St Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Georgiou","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"White","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"},{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-8147","authenticated-orcid":false,"given":"Guillaume","family":"Lessene","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"},{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-4873","authenticated-orcid":false,"given":"David C. S.","family":"Huang","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"},{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"},{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"},{"name":"Clinical Haematology, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, Parkville, Melbourne, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Geneste","sequence":"first","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Rasmussen","sequence":"first","affiliation":[{"name":"Cerberus Sciences, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4864-7033","authenticated-orcid":false,"given":"Melissa J.","family":"Davis","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"},{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-8617","authenticated-orcid":false,"given":"Paul G.","family":"Ekert","sequence":"first","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wei","sequence":"first","affiliation":[{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;"},{"name":"Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9690-0879","authenticated-orcid":false,"given":"Ashley P.","family":"Ng","sequence":"first","affiliation":[{"name":"The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia;"},{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"},{"name":"Clinical Haematology, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, Parkville, Melbourne, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong L.","family":"Khaw","sequence":"first","affiliation":[{"name":"Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia;"},{"name":"The Royal Children\u2019s Hospital, Parkville, Melbourne, Australia;"},{"name":"Murdoch Children\u2019s Research Institute, Parkville, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"issue":"15","key":"2020062216492895000_B1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"2020062216492895000_B2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2020062216492895000_B3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"28","key":"2020062216492895000_B4","doi-asserted-by":"crossref","first-page":"20075","DOI":"10.18632\/oncotarget.24744","article-title":"S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth","volume":"9","author":"Casara","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"2020062216492895000_B5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nchembio.1246","article-title":"Structure-guided design of a selective BCL-X(L) inhibitor","volume":"9","author":"Lessene","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"7626","key":"2020062216492895000_B6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"1","key":"2020062216492895000_B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"suppl_1","key":"2020062216492895000_B8","article-title":"Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed\/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma [abstract]","volume":"134","author":"Lacayo","year":"2019","journal-title":"Blood"},{"issue":"35","key":"2020062216492895000_B9","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1074\/jbc.R117.799056","article-title":"Dysregulation of BCL-2 family proteins by leukemia fusion genes","volume":"292","author":"Brown","year":"2017","journal-title":"J Biol Chem"},{"issue":"12","key":"2020062216492895000_B10","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep"},{"issue":"10","key":"2020062216492895000_B11","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2020062216492895000_B12","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2012-06-440230","article-title":"Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia","volume":"122","author":"Koss","year":"2013","journal-title":"Blood"},{"issue":"354","key":"2020062216492895000_B13","doi-asserted-by":"crossref","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"8","author":"Leonard","year":"2016","journal-title":"Sci Transl Med"},{"issue":"20","key":"2020062216492895000_B14","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"2020062216492895000_B15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020062216492895000_B16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2020062216492895000_B17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"2020062216492895000_B18","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1182\/blood-2009-02-204818","article-title":"Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML","volume":"114","author":"Powell","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2020062216492895000_B19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1354\/vp.09-VP-0016-R-DEX","article-title":"Diagnostic exercise: sudden death in a mouse with experimentally induced acute myeloid leukemia","volume":"46","author":"Radaelli","year":"2009","journal-title":"Vet Pathol"},{"issue":"3","key":"2020062216492895000_B20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/0192623310362249","article-title":"Case series: acute tumor lysis syndrome in mutator mice with disseminated lymphoblastic lymphoma","volume":"38","author":"Treuting","year":"2010","journal-title":"Toxicol Pathol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/12\/2762\/1745844\/advancesadv2019001416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/12\/2762\/1745844\/advancesadv2019001416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T20:49:41Z","timestamp":1592858981000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/12\/2762\/461057\/Cotargeting-BCL2-and-MCL1-in-highrisk-BALL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001416","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]}}}